Search
Search Results
-
Personalized Treatment of Multiple Myeloma in Frail Patients
Purpose of ReviewAs the treatment landscape for multiple myeloma (MM) continues to expand at a rapid pace, management of older adults and frail...
-
Assessment tools for patient-reported outcomes in multiple myeloma
BackgroundPatients with multiple myeloma experience severe symptom burden. Patient participation in self-reporting is essential as medical staff’s...
-
ASH highlights 2022—multiple myeloma
The 64th annual meeting was held in New Orleans, Louisiana from December 10–13, 2022. More than 150 abstracts concerning multiple myeloma have been...
-
Potential Clinical Role of LncRNA miR503HG in Multiple Myeloma and its Effect on the Proliferation and Adhesion of Myeloma Cells
This study mainly explored the role of lncRNA miR503HG in multiple myeloma and the potential downstream regulatory mechanism affecting disease....
-
Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth
The hypercoagulable state is a hallmark for patients with multiple myeloma (MM) and is associated with disease progression. Activated platelets...
-
Bispecific antibodies for multiple myeloma: past, present and future
Despite the development of various therapeutic agents, multiple myeloma remains incurable. Recently, T-cell redirected immunotherapy has become a...
-
The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
Maintenance therapies in multiple myeloma improve survival after induction treatment. This study characterizes the strategies for maintenance therapy...
-
How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership
BackgroundOver the last decade there has been considerable research into the treatment, management, and quality of life of people living with...
-
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune...
-
Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
The persistence of tumor load in multiple myeloma (MM) lead to relapse in patients achieving complete remission (CR). Appropriate and effective...
-
Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
Venous thromboembolism (VTE) poses a significant challenge in the context of multiple myeloma, with an incidence of up to 10% in newly diagnosed...
-
Correlation Between Bariatric Surgery and the Risk of Multiple Myeloma: Results from an Evidence-Based Strategy
ObjectiveWe conducted a meta-analysis of current literature to assess whether bariatric surgery(BS) has a positive effect on reducing the risk of...
-
Severe hypoglycemia due to insulin auto-antibodies of newly diagnosed multiple myeloma: A case report
ObjectiveInsulin autoimmune syndrome (IAS) is a rare condition that can be overlooked in the differential diagnosis of hypoglycemia. Hematologic...
-
An MRI-based radiomics nomogram for differentiating spinal metastases from multiple myeloma
BackgroundSpinal metastasis and multiple myeloma share many overlap** conventional radiographic imaging characteristics, thus, their...
-
Occurrence of Monoclonal Band in Alpha Region on Serum Electrophoresis in Multiple Myeloma: A Diagnostic Conundrum
The presence of an M-band in serum and/or urine electrophoresis is a crucial diagnostic indicator for multiple myeloma and other plasma cell...
-
Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast
Immunotherapies have significantly improved outcomes in patients with multiple myeloma yet maintaining a durable response in heavily pretreated...
-
The core symptom in multiple myeloma patients undergoing chemotherapy: a network analysis
BackgroundDuring chemotherapy for multiple myeloma, symptoms include those related to the disease, as well as adverse effects of the treatment. Few...
-
Widespread presentation of brown tumors mimicking multiple myeloma
Brown tumors or osteitis fibrosa cystica has become a rare presentation of primary hyperparathyroidism in up-to-date clinical practice. Here, we...
-
Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma
Selinexor [Nexpovio ® (EU); Xpovio ® (USA)] is a first-in-class, selective exportin-1 inhibitor. Oral selinexor once weekly in combination with...
-
Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma
Multiple myeloma (MM) is accompanied by alterations to the normal plasma cell (PC) proteome, leading to changes to the tumor microenvironment and...